Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06342128

Molecular Landscape of Microvascular Inflammation in Kidney Allografts

Comprehensive Multiscale Characterization of the Molecular Landscape of Microvascular Inflammation in Kidney Allografts

Status
Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Paris Translational Research Center for Organ Transplantation · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Microvascular inflammation in kidney allografts has been widely reappraised in the recent update of Banff classification. There is a critical need to better understand the pathophysiological mechanisms associated with the various phenotypes of microvascular inflammation that are observed in kidney transplants, particularly in order to develop targeted therapeutic approaches.

Detailed description

Antibody-mediated rejection is a major cause of graft failure in kidney transplant recipients. The diagnostic criteria for antibody-mediated rejection have undergone significant changes since their initial definition in the international Banff Classification system. The Banff 2022 Classification update reappraises lesions of microvascular inflammation and identifies new phenotypes for cases with microvascular inflammation. However, pathophysiological mechanisms associated with microvascular inflammation in kidney allografts are still poorly understood, thus hampering the development of efficient treatments. The aims of this study are: 1. To decipher the spatial immune-molecular landscape of microvascular inflammation in kidney allografts. 2. To compare the characteristics of this landscape in different clinical scenarios. The investigators will use a multimodal phenotyping approach including histological analyses and multiplex immunostainings, bulk transcriptomic analyses and spatial whole-transcriptome digital profiling to decipher the molecular landscape of microvascular inflammation in kidney allografts. Based on these results, they will investigate its association with allograft outcomes and search for molecular targets which could benefit from targeted therapeutic strategies.

Conditions

Interventions

TypeNameDescription
OTHERNo interventionNo intervention

Timeline

Start date
2022-01-01
Primary completion
2024-06-01
Completion
2025-12-01
First posted
2024-04-02
Last updated
2025-05-31

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06342128. Inclusion in this directory is not an endorsement.